Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002613326 | SCV002954730 | uncertain significance | Vici syndrome | 2022-02-11 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 2395 of the EPG5 protein (p.Val2395Met). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The methionine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. This variant has not been reported in the literature in individuals affected with EPG5-related conditions. This variant is present in population databases (rs753475634, gnomAD 0.0009%). |
Ambry Genetics | RCV002613327 | SCV003670936 | uncertain significance | Inborn genetic diseases | 2022-12-13 | criteria provided, single submitter | clinical testing | The c.7183G>A (p.V2395M) alteration is located in exon 41 (coding exon 41) of the EPG5 gene. This alteration results from a G to A substitution at nucleotide position 7183, causing the valine (V) at amino acid position 2395 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |